OncoResponse
PrivateLast Round
VC Round
May 18, 2023
Total Funding Raised
$169.36M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
OncoResponse is a biotechnology company that develops cancer immunotherapies by leveraging insights from the immune systems of patients who have shown exceptional responses to checkpoint inhibition.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OncoResponse Comparables
Compare OncoResponse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alchemab Therapeutics | 88% | |
| Tizona Therapeutics | 83% | |
| Adanate | 82% |
OncoResponse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 18, 2023 | ||||
| Grant | May 17, 2023 | ||||
| Debt | Feb 16, 2022 | ||||
| Series C | Mar 31, 2021 | ||||
| Series B | Sep 11, 2018 | ||||
Series A | Mar 9, 2017 |
Key People
Founding team and executive leadership
OncoResponse Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series B |
| GreatPoint Ventures | Series A |
| InterVest | VC Round |
| Cancer Prevention & Research Institute of Texas | Grant |
| HT Family Office | Series B |
| Magnetar Capital | Series C |
| Yonjin Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 48% MoM.
- Apr 22, 2026
Monthly visitors grew 70% MoM, from 667 to 1.1K.
OncoResponse Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OncoResponse's valuation, stock price, and market status.
Is OncoResponse a public or private company?
OncoResponse is a private company.
What is the current stock price of OncoResponse?
OncoResponse is a private company with no public stock price. No recent secondary market data is available.
How much is OncoResponse worth (valuation)?
Valuation information for OncoResponse is not publicly available.
Can I buy OncoResponse stock?
OncoResponse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was OncoResponse's last funding round?
OncoResponse's most recent funding round was VC Round on May 18, 2023.
Who are the main investors in OncoResponse?
Key investors in OncoResponse include 3B FUTURE Health Fund, ARCH Venture Partners, RiverVest Venture Partners, Canaan Partners, Helvetic Trust AG.
Will OncoResponse IPO soon?
No public IPO plans have been announced for OncoResponse.
How can I track OncoResponse secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OncoResponse's secondary market activity and sign up for updates.